Versor Investments LP Decreases Stake in Sotera Health Company $SHC

Versor Investments LP cut its stake in Sotera Health Company (NASDAQ:SHC) by 69.1% in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 14,000 shares of the company’s stock after selling 31,300 shares during the period. Versor Investments LP’s holdings in Sotera Health were worth $220,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds have also bought and sold shares of SHC. Sculptor Capital LP lifted its stake in shares of Sotera Health by 27.2% during the second quarter. Sculptor Capital LP now owns 11,500,000 shares of the company’s stock worth $127,880,000 after buying an additional 2,462,489 shares during the period. Norges Bank purchased a new position in Sotera Health in the 2nd quarter worth $9,607,000. Two Seas Capital LP lifted its position in Sotera Health by 21.1% during the 2nd quarter. Two Seas Capital LP now owns 4,020,867 shares of the company’s stock worth $44,712,000 after acquiring an additional 699,731 shares during the period. Bank of America Corp DE grew its stake in Sotera Health by 40.2% during the 2nd quarter. Bank of America Corp DE now owns 916,156 shares of the company’s stock valued at $10,188,000 after purchasing an additional 262,772 shares during the last quarter. Finally, Voss Capital LP increased its holdings in shares of Sotera Health by 50.0% in the second quarter. Voss Capital LP now owns 750,000 shares of the company’s stock valued at $8,340,000 after purchasing an additional 250,000 shares during the period. Institutional investors and hedge funds own 91.03% of the company’s stock.

Insider Transactions at Sotera Health

In other Sotera Health news, Director Gtcr Investment Xi Llc sold 6,480,000 shares of the stock in a transaction that occurred on Wednesday, December 3rd. The stock was sold at an average price of $16.33, for a total transaction of $105,818,400.00. Following the transaction, the director owned 22,735,301 shares in the company, valued at approximately $371,267,465.33. This represents a 22.18% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Pincus & Co. Warburg sold 9,720,000 shares of the firm’s stock in a transaction that occurred on Wednesday, December 3rd. The shares were sold at an average price of $16.33, for a total value of $158,727,600.00. Following the completion of the sale, the director directly owned 34,102,952 shares in the company, valued at approximately $556,901,206.16. The trade was a 22.18% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 17,384,104 shares of company stock valued at $284,024,511 in the last ninety days. 47.55% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

A number of equities research analysts recently commented on the company. BMO Capital Markets initiated coverage on Sotera Health in a report on Thursday, November 13th. They set an “outperform” rating and a $19.00 target price for the company. Piper Sandler raised shares of Sotera Health from a “neutral” rating to an “overweight” rating and raised their price target for the stock from $17.00 to $24.00 in a research report on Friday, January 9th. Zacks Research downgraded shares of Sotera Health from a “strong-buy” rating to a “hold” rating in a report on Friday, January 30th. Royal Bank Of Canada assumed coverage on shares of Sotera Health in a research note on Thursday, January 8th. They issued an “outperform” rating and a $24.00 price objective on the stock. Finally, Weiss Ratings restated a “hold (c-)” rating on shares of Sotera Health in a research report on Monday, December 29th. Seven equities research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $20.00.

Sotera Health Price Performance

NASDAQ:SHC opened at $17.12 on Friday. The company has a debt-to-equity ratio of 4.04, a current ratio of 2.38 and a quick ratio of 2.18. The company has a 50 day moving average price of $17.92 and a 200-day moving average price of $16.52. Sotera Health Company has a 1-year low of $9.53 and a 1-year high of $19.85. The firm has a market cap of $4.86 billion, a price-to-earnings ratio of 90.11 and a beta of 1.82.

Sotera Health Company Profile

Sotera Health Inc (NASDAQ: SHC) is a global provider of sterilization and laboratory testing services that support the medical device, pharmaceutical, life sciences and consumer product industries. Headquartered in Jacksonville, Florida, the company offers a suite of services designed to ensure products meet rigorous safety and regulatory requirements before reaching market.

Sotera Health operates through three primary service platforms. Its Sterigenics division delivers contract sterilization solutions, including ethylene oxide (EtO), gamma irradiation, electron beam and X-ray technologies.